

# Val Gebski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1795888/publications.pdf>

Version: 2024-02-01

269  
papers

22,215  
citations

17405

63  
h-index

9311

143  
g-index

273  
all docs

273  
docs citations

273  
times ranked

25232  
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. <i>Lancet Oncology</i> , The, 2011, 12, 681-692.	5.1	1,467
2	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	5.1	1,376
3	Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1895-1904.	13.9	1,274
4	Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. <i>Lancet Oncology</i> , The, 2007, 8, 226-234.	5.1	1,137
5	Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. <i>Lancet Oncology</i> , The, 2005, 6, 659-668.	5.1	876
6	Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1356.	3.8	835
7	Checkpoint Inhibitors in Metastatic EGFR- Mutated Non-“Small Cell Lung Cancer” A Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, 403-407.	0.5	653
8	Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 1987, 317, 1490-1495.	13.9	546
9	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 3323-3329.	0.8	500
10	Impact of EGFR Inhibitor in Non-“Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 595-605.	3.0	469
11	SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1913-1921.	0.8	467
12	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-“Small Cell Lung Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 210.	3.4	437
13	Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2497.	3.8	393
14	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3191-3198.	0.8	370
15	Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2016, 388, 1408-1416.	6.3	321
16	Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. <i>Diabetologia</i> , 2011, 54, 280-290.	2.9	304
17	Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 772-780.	5.1	296
18	Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2190.	3.8	294

#	ARTICLE	IF	CITATIONS
19	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	5.1	293
20	SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1723-1731.	0.8	289
21	Impact of Specific Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in <i>EGFR</i>-Mutant Lung Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1958-1965.	0.8	280
22	Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1224.	3.8	271
23	Surgery and Adjuvant Radiotherapy in Patients with Cutaneous Head and Neck Squamous Cell Carcinoma Metastatic to Lymph Nodes: Combined Treatment Should be Considered Best Practice. <i>Laryngoscope</i> , 2005, 115, 870-875.	1.1	257
24	Delayed versus Immediate Cord Clamping in Preterm Infants. <i>New England Journal of Medicine</i> , 2017, 377, 2445-2455.	13.9	228
25	Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer. <i>Annals of Surgery</i> , 2019, 269, 596-602.	2.1	210
26	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	196
27	TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. <i>Annals of Surgical Oncology</i> , 2017, 24, 2252-2258.	0.7	186
28	Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. <i>British Journal of Cancer</i> , 2012, 107, 588-591.	2.9	170
29	Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 32-45.	5.5	164
30	Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2011, 12, 1240-1248.	5.1	162
31	Outcomes of Two Trials of Oxygen-Saturation Targets in Preterm Infants. <i>New England Journal of Medicine</i> , 2016, 374, 749-760.	13.9	161
32	A Phase III Randomized Clinical Trial Comparing Laparoscopic or Robotic Radical Hysterectomy with Abdominal Radical Hysterectomy in Patients with Early Stage Cervical Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2008, 15, 584-588.	0.3	144
33	TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international,) Tj ETQq1 1 0.784314 rg34 /Overlo		
34	Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4498-4504.	0.8	131
35	Randomisation in clinical trials. <i>Medical Journal of Australia</i> , 2002, 177, 565-567.	0.8	130
36	Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. <i>British Journal of Cancer</i> , 2013, 109, 147-153.	2.9	130

#	ARTICLE	IF	CITATIONS
37	Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. <i>Clinical Nutrition</i> , 2014, 33, 581-587.	2.3	125
38	Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature. <i>Gynecologic Oncology</i> , 2012, 125, 263-270.	0.6	124
39	The effect of waiting for radiotherapy for grade III/IV gliomas. <i>Radiotherapy and Oncology</i> , 2000, 57, 131-136.	0.3	123
40	MERKEL CELL CARCINOMA: IMPROVED OUTCOME WITH ADJUVANT RADIOTHERAPY. <i>ANZ Journal of Surgery</i> , 2005, 75, 275-281.	0.3	122
41	Metastatic cutaneous squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2009, 115, 1883-1891.	2.0	122
42	Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 633-643.	0.5	122
43	Determining the sample size in a clinical trial. <i>Medical Journal of Australia</i> , 2002, 177, 256-257.	0.8	117
44	The Role of Radiotherapy Alone in Patients With Merkel Cell Carcinoma: Reporting the Australian Experience of 43 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 703-709.	0.4	117
45	Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. <i>Obstetrics and Gynecology</i> , 2002, 99, 1008-1013.	1.2	115
46	Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective. <i>Journal of the National Cancer Institute</i> , 2006, 98, 26-38.	3.0	115
47	Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. <i>Statistics in Medicine</i> , 2001, 20, 661-684.	0.8	113
48	Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2018, 19, 1126-1134.	5.1	113
49	Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGTC ATTAX trial. <i>British Journal of Cancer</i> , 2010, 102, 475-481.	2.9	106
50	Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis*. <i>Critical Care Medicine</i> , 2011, 39, 2678-2683.	0.4	105
51	Treatment Efficacy of Sacral Nerve Stimulation in Slow Transit Constipation: A Two-Phase, Double-Blind Randomized Controlled Crossover Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 733-740.	0.2	103
52	Thromboembolic complications in patients with clear cell carcinoma of the ovary. <i>Gynecologic Oncology</i> , 2007, 104, 406-410.	0.6	99
53	The prognostic value of pimonidazole and tumour pO <sub>2</sub> in human cervix carcinomas after radiation therapy: A prospective international multi-center study. <i>Radiotherapy and Oncology</i> , 2006, 80, 123-131.	0.3	98
54	Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1505-1512.	0.8	95

#	ARTICLE	IF	CITATIONS
55	Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. <i>European Journal of Cancer</i> , 2012, 48, 1147-1153.	1.3	86
56	Outcome and Patterns of Recurrence for International Federation of Gynecology and Obstetrics (FIGO) Stages I and II Squamous Cell Vulvar Cancer. <i>Obstetrics and Gynecology</i> , 2009, 113, 895-901.	1.2	85
57	Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. <i>Head and Neck</i> , 2012, 34, 1524-1528.	0.9	84
58	Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. <i>Radiotherapy and Oncology</i> , 2007, 83, 389-397.	0.3	80
59	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580.	3.2	79
60	Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 249.e1-249.e10.	0.7	78
61	Modelling interrupted time series to evaluate prevention and control of infection in healthcare. <i>Epidemiology and Infection</i> , 2012, 140, 2131-2141.	1.0	72
62	Does waiting time affect the outcome of larynx cancer treated by radiotherapy?. <i>Radiotherapy and Oncology</i> , 1997, 44, 137-141.	0.3	69
63	Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002388.	3.9	67
64	Adjuvant locoregional radiotherapy as best practice in patients with Merkel cell carcinoma of the head and neck. <i>Head and Neck</i> , 2005, 27, 208-216.	0.9	66
65	Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1253-1262.	3.0	64
66	Dynamic balancing randomization in controlled clinical trials. <i>Statistics in Medicine</i> , 2005, 24, 3729-3741.	0.8	63
67	Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. <i>Cancer Research</i> , 2021, 81, 3461-3479.	0.4	62
68	Sustained Reduction in the Clinical Incidence of Methicillin-Resistant <i>Staphylococcus aureus</i> Colonization or Infection Associated with a Multifaceted Infection Control Intervention. <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 1-8.	1.0	60
69	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study. <i>Clinical Cancer Research</i> , 2016, 22, 3164-3171.	3.2	60
70	The Chinese herbal formulation Biminne in management of perennial allergic rhinitis: a randomized, double-blind, placebo-controlled, 12-week clinical trial. <i>Annals of Allergy, Asthma and Immunology</i> , 2002, 88, 478-487.	0.5	59
71	Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. <i>Annals of Oncology</i> , 2014, 25, 117-121.	0.6	57
72	Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2020, 21, 851-860.	5.1	57

#	ARTICLE	IF	CITATIONS
73	Merkel cell carcinoma: An Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 33-40.	0.6	56
74	Environmental, Personal, and Genetic Determinants of Response to Vitamin D Supplementation in Older Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1332-E1340.	1.8	56
75	The Head Injury Retrieval Trial (HIRT): a single-centre randomised controlled trial of physician prehospital management of severe blunt head injury compared with management by paramedics only. <i>Emergency Medicine Journal</i> , 2015, 32, 869-875.	0.4	55
76	Effect of long-term mobile communication microwave exposure on vascular permeability in mouse brain. <i>Pathology</i> , 2002, 34, 344-347.	0.3	54
77	ANTERIOR TONGUE CANCER AND THE INCIDENCE OF CERVICAL LYMPH NODE METASTASES WITH INCREASING TUMOUR THICKNESS: SHOULD ELECTIVE TREATMENT TO THE NECK BE STANDARD PRACTICE IN ALL PATIENTS?. <i>ANZ Journal of Surgery</i> , 2005, 75, 101-105.	0.3	54
78	Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIFLOX study. <i>BMC Cancer</i> , 2014, 14, 897.	1.1	54
79	Glycosylated haemoglobin for screening and diagnosis of gestational diabetes mellitus. <i>BMJ Open</i> , 2016, 6, e011059.	0.8	54
80	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	1.0	54
81	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264.	0.8	52
82	HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2351-2358.	4.3	50
83	Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 941-944.	2.0	48
84	Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. <i>Gynecologic Oncology</i> , 2021, 161, 143-151.	0.6	46
85	Presenting symptoms of epithelial ovarian cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005, 45, 211-214.	0.4	43
86	Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. <i>British Journal of Cancer</i> , 2016, 114, 505-509.	2.9	43
87	Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. <i>Annals of Oncology</i> , 2017, 28, 1842-1848.	0.6	43
88	Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 310-318.	5.5	43
89	Left-sided breast cancer loco-regional radiotherapy with deep inspiration breath-hold: Does volumetric-modulated arc radiotherapy reduce heart dose further compared with tangential intensity-modulated radiotherapy?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 545-553.	0.9	41
90	Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 5-9.	0.7	41

#	ARTICLE	IF	CITATIONS
91	Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2014, 99, 156-161.	2.2	40
92	Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. <i>British Journal of Cancer</i> , 2010, 102, 1341-1347.	2.9	39
93	Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. <i>Annals of Oncology</i> , 2012, 23, 2020-2027.	0.6	39
94	Quality of Life After Complete Lymphadenectomy for Vulvar Cancer: Do Women Prefer Sentinel Lymph Node Biopsy?. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 813-819.	1.2	39
95	Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. <i>Gynecologic Oncology</i> , 2015, 136, 18-24.	0.6	39
96	Stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring: the TROG 15.01 SPARK trial. <i>BMC Cancer</i> , 2017, 17, 180.	1.1	39
97	Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. <i>Annals of Oncology</i> , 2020, 31, 236-245.	0.6	39
98	Protection against recurrent acute bronchitis after oral immunization with killed <i>Haemophilus influenzae</i> . <i>Medical Journal of Australia</i> , 1990, 152, 413-416.	0.8	37
99	The utility of serum CA-125 in predicting extrauterine disease in apparent early-stage endometrial cancer. <i>International Journal of Cancer</i> , 2012, 131, 885-890.	2.3	35
100	Data maturity and follow-up in time-to-event analyses. <i>International Journal of Epidemiology</i> , 2018, 47, 850-859.	0.9	35
101	Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. <i>Medical Journal of Australia</i> , 2012, 196, 688-692.	0.8	34
102	Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. <i>Annals of Oncology</i> , 2016, 27, 1505-1510.	0.6	34
103	Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1338-1342.	3.0	33
104	Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. <i>European Journal of Cancer</i> , 2012, 48, 2155-2162.	1.3	33
105	Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaesist). <i>British Journal of Cancer</i> , 2017, 116, 455-463.	2.9	33
106	Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema. <i>Annals of Surgical Oncology</i> , 2017, 24, 1064-1070.	0.7	33
107	Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 530-538.	0.4	33
108	Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2011, 105, 1144-1150.	2.9	32

#	ARTICLE	IF	CITATIONS
109	A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, 937-943.	0.6	32
110	Parotid lymph-node metastases from cutaneous squamous-cell carcinomas: Treatment outcome and prognostic factors following surgery and adjuvant radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2002, 46, 174-179.	0.6	31
111	Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). <i>Annals of Oncology</i> , 2014, 25, 143-148.	0.6	31
112	Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. <i>British Journal of Cancer</i> , 2015, 112, 963-970.	2.9	31
113	The cost-effectiveness of total laparoscopic hysterectomy compared to total abdominal hysterectomy for the treatment of early stage endometrial cancer. <i>BMJ Open</i> , 2013, 3, e001884.	0.8	29
114	High-resolution lymphoscintigraphy is essential for recognition of the significance of internal mammary nodes in breast cancer. <i>Annals of Oncology</i> , 2009, 20, 977-984.	0.6	28
115	Carboplatin+paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2011, 105, 360-365.	2.9	28
116	Early-stage squamous cell carcinoma of the lip: The Australian experience and the benefits of radiotherapy in improving outcome in high-risk patients after resection. <i>Head and Neck</i> , 2013, 35, 1426-1430.	0.9	28
117	Predicting vitamin D deficiency in older Australian adults. <i>Clinical Endocrinology</i> , 2013, 79, 631-640.	1.2	28
118	Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. <i>Annals of Oncology</i> , 2016, 27, 1733-1739.	0.6	28
119	Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. <i>Annals of Oncology</i> , 2017, 28, 1849-1855.	0.6	28
120	Disease-Free and Survival Outcomes for Total Laparoscopic Hysterectomy Compared With Total Abdominal Hysterectomy in Early-Stage Endometrial Carcinoma: A Meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 529-538.	1.2	28
121	The importance of censoring in competing risks analysis of the subdistribution hazard. <i>BMC Medical Research Methodology</i> , 2017, 17, 52.	1.4	26
122	Recruitment and Results of a Pilot Trial of Vitamin D Supplementation in the General Population of Australia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4473-4480.	1.8	25
123	Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. <i>Supportive Care in Cancer</i> , 2013, 21, 1561-1568.	1.0	25
124	Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. <i>Journal of Translational Medicine</i> , 2013, 11, 189.	1.8	25
125	Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 1.	3.6	25
126	Prognostic Significance of Lymph Node Ratio in Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>Annals of Surgical Oncology</i> , 2016, 23, 1693-1698.	0.7	25



#	ARTICLE	IF	CITATIONS
127	Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 385-393.	1.1	25
128	Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 772-780.	2.2	25
129	Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. <i>International Journal of Obesity</i> , 2014, 38, 1165-1171.	1.6	23
130	Sentinel Lymph Node Based Management or Routine Axillary Clearance? Three-year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial. <i>Annals of Surgical Oncology</i> , 2015, 22, 17-23.	0.7	22
131	COMmunication with Families regarding ORgan and Tissue donation after death in intensive care (COMFORT): protocol for an intervention study. <i>BMC Health Services Research</i> , 2017, 17, 42.	0.9	22
132	Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion. <i>Head and Neck</i> , 2018, 40, 985-992.	0.9	22
133	On the issue of "multiple" first failures in competing risks analysis. <i>Statistics in Medicine</i> , 2002, 21, 2243-2255.	0.8	21
134	Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: A meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 273-278.	0.7	21
135	Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. <i>Annals of Oncology</i> , 2016, 27, 806-812.	0.6	21
136	Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. <i>Gynecologic Oncology</i> , 2017, 144, 65-71.	0.6	21
137	Tumor depth of invasion versus tumor thickness in guiding regional nodal treatment in early oral tongue squamous cell carcinoma. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2020, 129, 45-50.	0.2	21
138	Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer. <i>JMIR Research Protocols</i> , 2017, 6, e43.	0.5	21
139	The misuse of mammography in the management of breast cancer revisited. <i>Medical Journal of Australia</i> , 1989, 151, 509-512.	0.8	20
140	Design of randomized controlled trials. <i>Journal of Fluency Disorders</i> , 2001, 26, 247-267.	0.7	20
141	Squamous Cell Carcinoma of the Lip in Australian Patients. <i>Dermatologic Surgery</i> , 2015, 41, 219-225.	0.4	20
142	Opposite associations between alanine aminotransferase and $\gamma$ -glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 783-793.	1.5	20
143	Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. <i>BMJ Open</i> , 2018, 8, e016700.	0.8	20
144	A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1595-1601.	1.2	20

#	ARTICLE	IF	CITATIONS
145	Internal mammary lymph node metastasis in breast cancer: Predictive models to assist with prognostic influence. <i>Breast</i> , 2011, 20, 278-283.	0.9	19
146	Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial. <i>Clinical Colorectal Cancer</i> , 2019, 18, 141-148.	1.0	19
147	Factorial designs: a graphical aid for choosing study designs accounting for interaction. <i>Clinical Trials</i> , 2004, 1, 315-325.	0.7	18
148	Clinical trials of interventional oncology—moving from efficacy to outcomes. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 93-104.	12.5	18
149	Radiation-induced oesophagitis in breast cancer: Factors influencing onset and severity for patients receiving supraclavicular nodal irradiation. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 113-119.	0.9	18
150	The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 2506-2515.	0.7	18
151	Increased plasma beta-thromboglobulin in patients with coronary artery vein graft occlusion: Response to low dose aspirin. <i>Journal of the American College of Cardiology</i> , 1990, 15, 1250-1258.	1.2	17
152	Patterns of metastases in familial and non-familial melanoma. <i>Melanoma Research</i> , 2003, 13, 105-109.	0.6	17
153	Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. <i>European Journal of Cancer</i> , 2011, 47, 1826-1836.	1.3	17
154	Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. <i>British Journal of Cancer</i> , 2013, 108, 771-774.	2.9	17
155	Prehospital response model and time to CT scan in blunt trauma patients; an exploratory analysis of data from the head injury retrieval trial. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2015, 23, 28.	1.1	17
156	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. <i>Gynecologic Oncology</i> , 2016, 142, 458-464.	0.6	17
157	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 936-944.	0.8	17
158	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 792-800.	0.5	17
159	Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. <i>European Journal of Cancer</i> , 2019, 117, 99-106.	1.3	17
160	Exaggeration of PFS by blinded, independent, central review (BICR). <i>Annals of Oncology</i> , 2019, 30, 332-338.	0.6	17
161	Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 359.	1.0	16
162	Cochrane vertebroplasty review misrepresented evidence for vertebroplasty with early intervention in severely affected patients. <i>BMJ Evidence-Based Medicine</i> , 2020, 25, 85-89.	1.7	16



#	ARTICLE	IF	CITATIONS
181	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , 2020, 139, 59-67.	1.3	12
182	An Australasian assessment of the basic treatment equivalent model derived from New South Wales data. <i>Journal of Medical Imaging and Radiation Oncology</i> , 1999, 43, 500-506.	0.6	11
183	Audiovisual biofeedback breathing guidance for lung cancer patients receiving radiotherapy: a multi-institutional phase II randomised clinical trial. <i>BMC Cancer</i> , 2015, 15, 526.	1.1	11
184	Protocol for a randomised control trial of bisphosphonate (zoledronic acid) treatment in childhood femoral head avascular necrosis due to Perthes disease. <i>BMJ Paediatrics Open</i> , 2017, 1, e000084.	0.6	11
185	VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. <i>JMIR Research Protocols</i> , 2017, 6, e17.	0.5	11
186	Elderly patients after they leave hospital. <i>Medical Journal of Australia</i> , 1986, 145, 251-254.	0.8	10
187	Randomised controlled trials: elements of a good study. <i>Medical Journal of Australia</i> , 2001, 175, 272-274.	0.8	10
188	The study protocol for the Head Injury Retrieval Trial (HIRT): a single centre randomised controlled trial of physician prehospital management of severe blunt head injury compared with management by paramedics. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2013, 21, 69.	1.1	10
189	Primary Surgical Management With Tailored Adjuvant Radiation for Stage IB2 Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2013, 121, 765-772.	1.2	10
190	How to train practising gynaecologists in total laparoscopic hysterectomy: protocol for the stepped-wedge IMAGINE trial. <i>BMJ Open</i> , 2019, 9, e027155.	0.8	10
191	Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 519-525.	1.1	9
192	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 313-319.	1.0	9
193	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021, 154, 190-200.	1.3	9
194	Management of oesophageal cancer at Westmead Hospital from 1979-1985. <i>Medical Journal of Australia</i> , 1988, 148, 450-456.	0.8	9
195	Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. <i>International Journal of Cardiology</i> , 2013, 168, 5378-5384.	0.8	8
196	Sentinel node biopsy and large (>3cm) breast cancer. <i>ANZ Journal of Surgery</i> , 2014, 84, 117-120.	0.3	8
197	Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. <i>Lung Cancer</i> , 2020, 150, 1-8.	0.9	8
198	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. <i>European Journal of Cancer</i> , 2021, 157, 278-290.	1.3	8

#	ARTICLE	IF	CITATIONS
199	Bladder Care in Palliative Care Inpatients: A Prospective Dual Site Cohort Study. <i>Palliative Medicine Reports</i> , 2020, 1, 251-258.	0.4	8
200	Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. <i>BMJ Open</i> , 2021, 11, e044656.	0.8	8
201	Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
202	Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2003, 47, 422-427.	0.6	7
203	Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. <i>International Journal of Obesity</i> , 2015, 39, 849-857.	1.6	7
204	Oral supplementation with bovine whey-derived Ig-rich fraction and lactoferrin improves SCORAD and DLQI in atopic dermatitis. <i>Journal of Dermatological Science</i> , 2017, 85, 143-146.	1.0	7
205	Pelvic floor functional outcomes after total abdominal vs total laparoscopic hysterectomy for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 419.e1-419.e14.	0.7	7
206	Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. <i>Lung Cancer</i> , 2021, 153, 35-41.	0.9	7
207	Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects?. <i>Medical Journal of Australia</i> , 2002, 177, 437-447.	0.8	6
208	Procalcitonin in intensive care units: the PRORATA trial. <i>Lancet, The</i> , 2010, 375, 1605.	6.3	6
209	Multilevel latent variable models for global health-related quality of life assessment. <i>Statistics in Medicine</i> , 2012, 31, 1249-1264.	0.8	6
210	Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1388-1396.	2.2	6
211	Monitoring distributional assumptions and early stopping for a prospective clinical trial using Monte Carlo simulation. <i>Statistics in Medicine</i> , 1987, 6, 667-678.	0.8	5
212	First-event or marginal estimation of cause-specific hazards for analysing correlated multivariate failure-time data?. <i>Statistics in Medicine</i> , 2008, 27, 922-936.	0.8	5
213	Influence of the Way Results Are Presented on Research Interpretation and Medical Decision Making: The PRIMER Collaboration Randomized Studies. <i>Medical Decision Making</i> , 2008, 28, 127-137.	1.2	5
214	Whole breast and excision cavity radiotherapy plan comparison: Conformal radiotherapy with sequential boost versus intensity-modulated radiation therapy with a simultaneously integrated boost. <i>Journal of Medical Radiation Sciences</i> , 2013, 60, 16-24.	0.8	5
215	Neoadjuvant chemotherapy with sequential anthracycline docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). <i>Breast</i> , 2014, 23, 142-151.	0.9	5
216	The SIRveNIB and SARAH trials and the role of SIR-Spheres Y-90 resin microspheres in the management of hepatocellular carcinoma. <i>Future Oncology</i> , 2017, 13, 2213-2216.	1.1	5

#	ARTICLE	IF	CITATIONS
217	Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring. <i>BMC Cancer</i> , 2021, 21, 494.	1.1	5
218	Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial. <i>BMC Cancer</i> , 2021, 21, 940.	1.1	5
219	Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. <i>World Journal of Gastroenterology</i> , 2015, 21, 5352.	1.4	5
220	Volumetric and dosimetric changes to salivary glands during radiotherapy for head and neck cancer. <i>Acta Oncol<sup>3</sup>gica</i> , 2015, 54, 1691-1693.	0.8	4
221	Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trial. <i>Journal of Clinical Epidemiology</i> , 2019, 112, 45-52.	2.4	4
222	Recurrent <sc>timeâ€toâ€event</sc> models with ordinal outcomes. <i>Pharmaceutical Statistics</i> , 2021, 20, 77-92.	0.7	4
223	EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 770022.	1.3	4
224	Criticisms of the VAPOUR trial in a recent commentary are unsubstantiated and incorrect. <i>Evidence-Based Medicine</i> , 2017, 22, 116-117.	0.6	3
225	Delayed Versus Immediate Cord Clamping in Preterm Infants. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 265-266.	0.2	3
226	Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 357-365.	1.1	3
227	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncol<sup>3</sup>gica</i> , 2020, 59, 20-27.	0.8	3
228	Effect of antibiotics on urine leakage in women with refractory detrusor overactivity: A phase IIb randomized trial. <i>Neurourology and Urodynamics</i> , 2021, 40, 158-167.	0.8	3
229	High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e044055.	0.8	3
230	Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. <i>Gynecologic Oncology</i> , 2021, 161, 502-507.	0.6	3
231	The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412110325.	0.9	3
232	A Randomized Trial Comparing Weekly With Every Second Week Sharp Debridement in People With Diabetes-Related Foot Ulcers Shows Similar Healing Outcomes: Potential Benefit to Resource Utilization. <i>Diabetes Care</i> , 2021, 44, e203-e205.	4.3	3
233	Statistical methods in clinical trials. <i>Medical Journal of Australia</i> , 2003, 178, 182-4.	0.8	3
234	Toward Incorporating Health-Related Quality of Life as Coprimary End Points in Clinical Trials: Time to Achieve Clinical Important Differences and QoL Profiles. <i>Journal of Clinical Oncology</i> , 2022, 40, 2378-2388.	0.8	3

#	ARTICLE	IF	CITATIONS
235	Long-Term Follow-Up of Patients Treated with Intermittent Hormone Therapy for Advanced Prostate Cancer. <i>Prostate Journal</i> , 1999, 1, 138-143.	0.2	2
236	Selective Mastectomy in the Management of Locally Advanced Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1010-1017.	0.4	2
237	Laparoscopy or laparotomy for early endometrial cancer? â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2010, 11, 1022-1023.	5.1	2
238	Decision making in older patients with advanced cancer: does doctor know best?. <i>Medical Journal of Australia</i> , 2012, 196, 35-36.	0.8	2
239	Evaluation of flexible and rigid (class solution) radiation therapy conformal prostate planning protocols. <i>Medical Dosimetry</i> , 2012, 37, 5-8.	0.4	2
240	Identification of doctors at risk of recurrent complaints: a national study of healthcare complaints in Australia. <i>BMJ Quality and Safety</i> , 2013, 22, 878-878.	1.8	2
241	Performance of four published risk models to predict sentinel lymph-node involvement in Australian women with early breast cancer. <i>Breast</i> , 2018, 41, 82-88.	0.9	2
242	Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysisâ€”Reply. <i>JAMA Oncology</i> , 2018, 4, 1138.	3.4	2
243	Long-term outcomes in 1121 Australian prostate cancer patients treated with definitive radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 116-123.	0.9	2
244	Using recurrent time-to-event models with multinomial outcomes to generate toxicity profiles. <i>Pharmaceutical Statistics</i> , 2021, 20, 840-849.	0.7	2
245	Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting. <i>European Journal of Cancer</i> , 2021, 148, 251-259.	1.3	2
246	Weight and weight control behaviors during long-term endometrial cancer survivorship: Results of the Laparoscopic Approach to Cancer of the Endometrium long-term follow-up study. <i>Cancer Medicine</i> , 2021, 10, 4896-4904.	1.3	2
247	In the future simulations will replace clinical trials. <i>Physical and Engineering Sciences in Medicine</i> , 2021, 44, 997-1001.	1.3	2
248	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 170, 169-178.	1.3	2
249	Secondary cytoreduction surgery for recurrent epithelial ovarian cancer. <i>Obstetrics and Gynecology</i> , 2002, 100, 1360.	1.2	1
250	RESPONSE: Re: Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1021-1022.	3.0	1
251	Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). <i>Annals of Oncology</i> , 2016, 27, 2302-2303.	0.6	1
252	Interfraction movement and clinical outcome of immobilization for thoracic irradiation: A randomized controlled trial. <i>Precision Radiation Oncology</i> , 2018, 2, 4-10.	0.4	1

#	ARTICLE	IF	CITATIONS
253	Re: Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying. <i>Internal Medicine Journal</i> , 2018, 48, 1414-1415.	0.5	1
254	Lowering the P Value Threshold. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 935.	3.8	1
255	A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trial. <i>Clinical Trials</i> , 2019, 16, 589-598.	0.7	1
256	Generalizability from well-designed RCTs underpin their scientific strength. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 663.	0.7	1
257	Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor 2-Positive Breast Cancer—Reply. <i>JAMA Oncology</i> , 2019, 5, 118.	3.4	1
258	Vertebroplasty has an important role in managing patients with severe pain when performed early and with appropriate technique. <i>Internal Medicine Journal</i> , 2020, 50, 647-648.	0.5	1
259	Patient-Specific Heart Constraint: A Tool for Optimization and Evaluation of Mean Heart Dose in Breast Cancer Patients. <i>Practical Radiation Oncology</i> , 2021, 11, e154-e162.	1.1	1
260	Complete pathological response following levonorgestrel intrauterine device in clinically stage I endometrial adenocarcinoma: Results of a randomized clinical trial. <i>Gynecologic Oncology</i> , 2021, 162, S43.	0.6	1
261	Trial Design: Should Randomized Phase III Trials in Gynecological Cancers Be Abandoned?. , 2014, , 263-284.		1
262	The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5627-TPS5627.	0.8	1
263	In reply: Determining the sample size in a clinical trial. <i>Medical Journal of Australia</i> , 2003, 178, 358-358.	0.8	0
264	Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836]. <i>European Journal of Cancer</i> , 2012, 48, 407.	1.3	0
265	Whole breast hypofractionation: Trials, guidelines and clinical practice. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 157-158.	0.9	0
266	Survival After Laparoscopic vs Abdominal Hysterectomy—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 574.	3.8	0
267	All-cause death in young women with endometrial cancer who receive progesterone therapy. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 119.	0.7	0
268	Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. <i>BMJ Open</i> , 2021, 11, e044656.	0.8	0
269	Clinical trial design in oncology: assessment of outcomes. <i>Lancet Oncology</i> , The, 2004, 5, 761-3.	5.1	0